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ABSTRACT
MicroRNAs (miRNAs) are short ( 22nt) RNAs that
impact gene expression by sequence-specific inter-
actions with messenger RNA or promoter
sequences of genomic DNA. Ectopic expression of
miRNAs can be accomplished by placing fragments
of the corresponding miRNA precursor under the
control of RNA polymerase II or III (RNAP II/III).
Here, we report that, in the absence of exogenous
promoters, DNA fragments incorporating miRNA
precursors can be delivered directly into a variety
of human cells and give rise to the corresponding
mature miRNA. Notably, the transcription of these
miRNA DNA fragments appears resistant to conven-
tional inhibitors of RNAP I/II/III activity. Taken
together, our findings suggest the existence of a
previously unrecognized atypical transcription
program for miRNA precursor sequences.
INTRODUCTION
Several hundred genes encoding miRNAs are currently
known for the human genome (1,2). Genes encoding
miRNAs are under the control of RNA polymerase II
or III (RNAPII/III) (3,4). According to the current
model of miRNA biogenesis, promoter occupancy leads
to the generation of a long primary transcript
(pri-miRNA) that is cleaved by the nuclear RNAase III
enzyme Drosha into a precursor-miRNA (pre-miRNA)
(5). The latter is exported to the cytoplasm where it is
cleaved by the enzyme Dicer to yield the mature,
single-stranded miRNA of 19–22nt in length, the end
eﬀector of gene expression (6–9). Here, we report on the
ability of a subgroup of miRNA precursors of 200–400nt
in length to self-transcribe in the absence of exogenous
promoters. In what follows, we examine the conditions
under which this phenomenon occurs and present our
ﬁndings from experiments with several miRNA/cell-line
combinations.
MATERIALS AND METHODS
Nucleic acid constructs
Polymerase chain reaction (PCR) ampliﬁcation for the
creation of the various miRNA amplicons were performed
in a 50-ml reaction mixture containing forward and reverse
primers at 2mM, 0.5U of pfu DNA polymerase
(Stratagene) and dNTP at 200mM. Constructs created in
this manner are denoted as Amp
miRNA-XX. Human
genomic DNA from HEK 293T cells (0.2mg) was used
as the sole template for creation of Amp
miRNA-XX
species. Primer sequences and the nucleotide length of
the resulting amplicons are shown in Supplementary
Table S1. The PCR reaction condition was 94 C for
3min, 36 cycles of 94 C for 30s, 60 C for 40s and 72 C
for 50s and 72 C for 5min. The PCR products were then
separated by electrophoresis in a 1.5% Tris–acetate–
EDTA (TAE) agarose gel, excised and gel-puriﬁed using
a commercial kit (Qiagen). RNAP II- and RNAP III-
promoter-driven miRNA-143 expression vectors were
created by digesting the pri-miRNA-143 amplicon with
BamH1 and EcoR I prior to cloning into pcDNA
(Invitrogen) and pSIREN-RetroQ (Clontech) vectors,
respectively. The chimeric miRNA-143/125a amplicon
was generated by placing miRNA-125a pri/pre sequence
in a 30 Pst1 site in the backbone of miRNA-143. The
backbone of miRNA-143 and 30a was altered such that
mature and (*) species were replaced by those encoding
the guide and passenger strands of siRNA targeting the
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constructs were directly synthesized as mini genes.
Sensors for assessing miRNA/siRNA activity were
created by inserting the respective antisense target
sequences of small RNA species in the 30-UTR of the
Renilla gene of psicheck-2 reporter vector (Promega)
which harbors Fireﬂy luciferase as an internal control.
Amp
miRNA-143 harboring a single nucleotide mutation in
position 16 of the mature miRNA was created using the
Quick-Change Site-Directed Mutagenesis kit (Stratagene).
Constructs were veriﬁed by DNA sequencing. The
Sanger miRBase Release 14.0 (September 2009) was
used as a reference for all miRNA nomenclature/
sequences. Short-hairpin RNA targeting RNAP I and
mitochondrial spRNAP-IV was created by inserting
the respective siRNA sequences into a generic shRNA
expression vector. All siRNA sequences are shown
in Supplementary Table S1. MiRNA amplicons
were incubated at 37 C for 1h with proteinase K
(600mAU/ml Qiagen) followed by enzymatic inactivation
by incubation at 75 C for 20min. Amplicons subsequently
underwent agarose gel puriﬁcation prior to cellular
transfection. Biotinylated constructs were created by
PCR by employing biotinylated primers. Amplicons
were then gel puriﬁed and equal molar amounts were
incubated with HEK 293T cell lysates. Streptavidin bead
preparation, immobilization of amplicons and release
of immobilized biotinylated molecules were performed
according to the manufacturer’s instructions
(Dynabeads MyOne
TM Streptavidin T1). Antibody
targeting RNAP II (Ab 8WG16) was used to visualize
association with the respective biotinylated constructs.
Cell culture and transfections
Human cell lines used in this study included HEK 293T,
Huh-7, HeLa, HCT116 and PBMC. Huh7, HEK 293T
and HeLa cells were cultured in DMEM/EMEM media,
respectively, supplemented with 10% (v/v) FBS and
2mML-glutamine. HCT116 cells were maintained in
McCoy’s 5A media supplemented with 10% (v/v) FBS.
PBMC, obtained from an anonymous donor through the
Rhode Island Blood Bank, were maintained in RPMI.
Vector, PCR amplicon and siRNA transfection was per-
formed by using Lipofectamine 2000 (Invitrogen) follow-
ing the manufacturer’s protocol for all cell lines. PBMC
was transfected using the Amaxa system (Amaxa
Biosystems). The absolute amount of DNA transfected
was 2mg/well (six-well plates) and 0.4mg/well (24-well
plates). The relative ratio of transfected product (ug)
was 1:1:0.25 for vectors, siRNA and amplicons, respec-
tively. POLR3A and irrelevant siRNA were obtained
from Santa Cruz and were initially transfected into
HEK 293T cells. Cells were subsequently re-seeded (at
24h) and then transfected with the various products (at
48h) prior to mature miRNA quantiﬁcation by real-time
(RT)-PCR at 72h. Actinomycin D and a-amanitin
(Sigma) were used at ﬁnal concentrations of 2mg/ml and
50mg/ml, respectively. All experiments involving miRNA
quantiﬁcation were performed in duplicate, independent
experiments and two replicate measurements were
associated with each experiment.
miRNA detection and quantiﬁcation
Northern blot. Ten to twenty micrograms of total RNA
extracted from HEK 293T cells using Trizol (Invitrogen)
was resolved on 15% SequaGel (National Diagnostics)
and transferred onto a GeneScreen Plus Hybridization
Transfer Membrane (PerkinElmer) in 0.5 TBE buﬀer.
The membrane was hybridized with (g-P
32) labeled
miRNA-speciﬁc antisense LNA (Exiqon) probe overnight
at 42 C in ULTRAhyb Ultrasensitive Hybridization
Buﬀer (Ambion). The membrane was washed sequentially
with 2% SSC containing 0.1% SDS three times and 0.1%
SSC containing 0.1% SDS three times, 10min for each
time at room temperature, and then exposed to Kodak
ﬁlm overnight at –80 C. The same membrane was
stripped with 0.1% SDS for 5min by microwave oven
and blocked with hybridization buﬀer and then hybridized
with the U6 snRNA probe (TGTGCTGCCGAAGCGAG
CAC) which served as a loading control.
RT PCR. TaqMan real time RT-PCR detection kits were
used to quantify mature miRNA levels in accordance with
manufacturer’s instructions (Applied Biosystems) and 18S
RNA was used for normalization.
RNA cloning. The miRCat-33 kit (IDT) was used to clone
mutated mature miRNA-143 from HEK 293T cells
transfected with the miRNA-143 mutant amplicon.
Brieﬂy, total RNA was extracted from cells at 48h after
transfection using Trizol (Invitrogen). Fifty micrograms of
total RNA was loaded on 12% denaturing PAGE gel (7M
Urea) running in 1 TBE at 125V for 1.5h.
Subsequently, the small RNA fraction was gel excised
and ligated to a 30 linker, re-puriﬁed and ﬁnally ligated
to a 50 linker. The ligated product was ampliﬁed, sub-
cloned into TOPO TA Cloning vector (Invitrogen) and
then sequenced.
Luciferase assays
Cells were seeded into 96-well plates 1day before
transfection. One-hundred nanograms of psicheck
reporter and 25ng Amp
miRNA-XX or 100ng plasmid were
transiently transfected into Huh7 or HEK 293T cells.
After 48h, luciferase activity was measured using the
Dual-Glo luciferase assay kit (Promega). Renilla luciferase
activity was normalized with ﬁreﬂy luciferase activity. All
sensor assays were performed as three independent exper-
iments. For each sensor experiment, a control employing
an empty vector construct (Ø) was used and corrected
luciferase values were averaged, arbitrarily set to a value
of ‘1’ and served as a reference for comparison of
fold-diﬀerences in experimental values.
50 Rapid ampliﬁcation of cDNA ends
50 rapid ampliﬁcation of cDNA ends (RACE) was per-
formed for identifying the primary transcripts of
Amp
miRNA-143-mut using the protocol suggested by the
manufacturer (Invitrogen). Brieﬂy, 1ug total RNA was
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into cDNA using miRNA-143 speciﬁc reverse primer
(50-accaggggaacttgtgtagag-30) and then puriﬁed by
S.N.A.P. Column. After addition of oligo-dC tail to
30 end of the puriﬁed cDNA with TdT (Terminal
deoxynucleotidyl transferase), PCR was performed with
a kit - provided forward primer and nested miRNA-143
speciﬁc primer (50-cacaagtggctgatagtatggagtc-30). Using a
1:100 dilution of the primary PCR product as template,
a second PCR was carried out with the same forward
primer and another nested miRNA-143 speciﬁc
primer (50-acttaccacttccaggctgatg-30). The products were
sub-cloned into TOPO TA Cloning vector (Invitrogen)
and then sequenced.
Statistical analysis
Mixed linear models (proc mixed, SAS version 9.2, SAS
Institute, Cary, NC, USA) were used to test for diﬀerences
among the various experimental conditions while account-
ing for replicates from each sample as having correlated
error. For example, nucleic acid species copy numbers
were log transformed (base 2) to stabilize variance and
thereby ensure that fold changes could be modeled as
additive. If conditions still had unequal variances despite
log transformation, the variance was modeled for each
condition individually within the model (heterogeneous
variance model). The choice between homogeneous and
heterogeneous variance models was based on which had
the lowest Bayesian information criteria (BIC) value. The
denominator degrees of freedom for models was based on
the Satterthwaite method (10). Parameters were estimated
based on residual estimation of maximum likelihood
(REML). The P-values for follow-up comparisons were
adjusted for alpha inﬂation from multiple comparisons
using the Bonferroni method to maintain family wise
alpha at 0.05.
RESULTS
Transcription of miRNA-143 in the absence of an
exogenous promoter
Originally, we set out to study miRNA-143. Our interest
in this miRNA stemmed from its low expression in a
number of cancers and a desire to better understand its
transcriptional control (Gao,J.S., manuscript in prepara-
tion) (11). For our experiments, we created a panel of
expression vectors by employing a previously described
strategy whereby a 316-nt sequence fragment that
included the full-length precursor for miRNA-143 was
placed under the control of a RNAP II or III (CMV or
U6) promoter in a plasmid (12). In parallel, we also
created PCR amplicons encompassing the RNAP II
(CMV) or RNAP III (U6) promoter and the 316-nt
fragment, mentioned above (Figure 1a). As expected,
both constructs led to mature miRNA-143 production
upon transfection into HEK 293T cells as lipoplexes. As
a control to the above experiments, we introduced the
316-nt long fragment as a PCR amplicon generated from
human genomic DNA (Amp
miRNA-143). To our surprise,
this amplicon, which contained no known exogenous
promoter element, led to the production of mature
miRNA-143 as assessed by both northern blot and real
time PCR, albeit at levels 100-fold lower than the RNAP
II/III-driven constructs (Figure 1b and c).
In order to ensure that Amp
miRNA-143 was indeed
contributing to the increased levels of mature
miRNA-143, we sought to distinguish the product
derived from Amp
miRNA-143 from any endogenous
miRNA-143. To this end, we introduced a single-
nucleotide mutation (T!C) at position 16 from the 50
end of the mature miRNA, a location that did not aﬀect
miRNA processing or production, as conﬁrmed by
northern blot (Supplementary Figure S1a and b). RNA
was isolated from cells transfected with the mutated,
promoter-less construct and small RNA species were
gel-excised, ligated to 50 and 30 linker molecules,
PCR-ampliﬁed and introduced into cloning vectors.
DNA sequencing of clones conﬁrmed the production of
the designed, ‘mutated’ variant of mature miRNA-143
(Supplementary Figure S1c).
While northern blots revealed RNA production from
our amplicons, we next sought to identify the sequence
of the primary transcript of Amp
miRNA-143. Thus, we
used RACE to analyze the 50-end of the primary transcript
in cells transfected with the amplicon. Importantly, for
these experiments, we again worked with the mutated
amplicon allowing us to diﬀerentiate RACE transcripts
corresponding to endogenous miRNA-143 production
from transcripts derived from Amp
miRNA-143-MUT. These
experiments revealed a complicated picture whereby ﬁve
transcripts were detected (Figure 1d). As expected, one of
the ﬁve transcripts was identical to the known
miRNA-143 precursor, whereas the others were slightly
longer. Presently, it remains unclear whether the shorter
RNA molecules detected in amplicon-transfected cells rep-
resent bona ﬁde primary transcript variants or result from
subsequent processing of the initial longer transcript.
Nevertheless, the RACE results contributed further
direct evidence that the miRNA amplicon was indeed
transcribed into RNA.
Determining the minimal length of Amp
miRNA-143 that
preserves its ability to self-transcribe
The amplicon used in the above-described experiments
was 316nt in length, i.e. substantially larger than the
length of the corresponding miRNA-143 precursor
sequence. Thus, we investigated whether shorter
amplicons also had the ability to self-transcribe and lead
to the biosynthesis of mature miRNA. A series of progres-
sively shorter, PCR-generated variants of Amp
miRNA-143
with truncations on both the 50- and 30-ends revealed that
a minimum length of 102nt was suﬃcient for production
of mature miRNA-143 following transfection into HEK
293T cells as assessed by RT-PCR (Figure 2b). Of the
26nt preceding miRNA-143* in the known miRNA-143
precursor, a minimum of 12nt directly adjacent to
miRNA-143* was required in order for the (truncated)
amplicon to be functional.
The functionality of the shorter molecules allowed us to
determine whether synthetic oligonucleotides encoding
Nucleic Acids Research,2010, Vol.38, No. 9 2777miRNA-143 could also lead to mature miRNA synthesis
upon cellular introduction. Oligonucleotides encoding
truncated construct B (116nt length) were commercially
synthesized, annealed and transfected into HEK 293T
cells. Surprisingly, Oligo
miRNA-143-B led to mature
miRNA-143 levels comparable to those associated with
the PCR generated Amp
miRNA-143-B (Figure 2c). All
PCR-generated amplicons used human genomic DNA as
a template and were gel excised and puriﬁed prior to
transfection. To eliminate the theoretical possibility that
bacterial proteins in the PCR reaction were transferred
along with the resulting amplicons, we subjected
Amp
miRNA-143-B to proteinase K digestion prior to
transfection. As seen in Figure 2c, such treatment had
no eﬀect upon its biosynthetic capacity.
A broad range of human cells support the atypical
transcription of miRNA-143 and other miRNAs
We next sought to determine whether transcription of
Amp
miRNA-143 was restricted to certain cell types only
(e.g. HEK 293T cells). Quantiﬁcation of mature
miRNA-143 in a variety of human cells with relatively
low levels of endogenous expression (e.g. PBMC, Huh-7,
Figure 1. Detection and functional analysis of Amp
miRNA-143.( a) A color-coded schema of the 316-nt pri-miRNA-143 DNA fragment is shown. Blue
shaded areas correspond to regions ﬂanking the miRNA-143 precursor (gray shade). Nucleotide sequences as follows: miRNA-143 (green),
miRNA-143* (purple), intervening loop (red), sequences of the precursor miRNA adjacent to the mature miRNA-143/143* (black) and sequences
adjacent to miRNA-143 precursor (blue). Expression constructs were made using the pri-miRNA-143 DNA fragment. Pla
CMV-miRNA-143 denotes a
conventional plasmid in which 316nt of pri-miRNA-143 was placed under the transcriptional control of RNAP II (CMV). Amp
CMV-miRNA-143 refers
to a PCR amplicon generated by selectively amplifying the CMV promoter and adjoining pri-miRNA-143 sequence from Pla
CMV-miR-143. Similar
constructs were made using RNAP III (U6) promoter. Amp
miRNA-143 was generated by selectively amplifying pri-miRNA-143 from human genomic
DNA and thus did not include any exogenous promoter elements. (b, c) Mature miRNA-143 biogenesis by Pla
CMV-miRNA-143, Amp
CMV-miRNA-143 and
Amp
miRNA-143 as assessed by northern blot (b) and real-time PCR (c) after introduction into HEK 293T cells. All constructs were transfected into
cells as lipoplexes and RNA was harvested at 48h. Northern blot utilized an LNA miRNA-143 probe and revealed no detectable endogenous mature
miRNA-143 in cells transfected with an empty vector (Ø), and variable levels produced by Pla
CMV-miRNA-143, Amp
CMV-miRNA-143 and Amp
miRNA-143.
Cells transfected with an irrelevant miRNA amplicon (Amp
miRNA-363) served as a negative control. M=markers corresponding to 20 and 60nt. U6
RNA was used as a loading control. (c) Real-time PCR was used to quantify levels of mature miRNA-143. Introduction of Amp
miRNA-143 into HEK
293T cells led to a statistically signiﬁcant increase in mature miRNA levels compared to cells that had been transfected with an empty vector (Ø)
(P<0.005) but at levels below that associated with Pla
CMV-miRNA-143 and Amp
CMV-miRNA-143. All experiments were performed in duplicate and are
shown as mean values and 95% CI. (d)5 0 RACE results of primary miRNA-143 transcripts in amplicon transfected cells. We utilized the mutated
miRNA-143 (Amp
miRNA-143-MUT) construct to allow diﬀerentiation from any endogenous miRNA-143 transcription. Arrows indicate the putative
transcription start site(s) of Amp
miRNA-143-MUT. Primary sequence data revealed the presence of the single nucleotide mutation at 50 position 15 of the
mature miRNA-143 (boxed) in analyzed clones. Asterisk indicates the start of pre-miRNA-143. Color scheme identical to that used in Figure 1a.
Underlined sequence corresponds to reverse primers used in the nested PCR reaction. The number of clones associated with each sequence is noted
in parenthesis.
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miRNA-143 readily
conﬁrmed its biosynthetic capacity in these cell types as
well (Figure 3a). In each case, Amp
miRNA-143 introduction
was associated with a statistically signiﬁcant increase in
mature miRNA-143 levels compared to cells that had
been transfected with an empty vector.
To determine whether atypical transcription was lim-
ited to miRNA-143, we generated and tested additional
PCR amplicons comprising miRNAs with relatively
low endogenous expression in HEK 293T cells:
Amp
miRNA-363, Amp
miRNA-145 and Amp
miRNA-517a.I n
each case, the respective amplicons produced the corre-
sponding mature miRNA in a statistically signiﬁcant
fashion just like Amp
miRNA-143 as assessed by RT-PCR
(Figure 3b).
We next created a PCR amplicon for miRNA-125a,
which is expressed at relatively ‘high’ levels in HEK
293T cells. Here, RT-PCR conﬁrmed that, as expected,
amplicon transfection did not lead to any appreciable
increase in the already high endogenous mature miRNA
levels. However, when we introduced Amp
miRNA-125a into
Huh-7 cells that are characterized by low endogenous
levels of miRNA-125a, we observed a signiﬁcant
(>1000-fold) increase in its expression (Figure 3c). We
also made a similar observation for the endogenously
abundant, liver-speciﬁc miRNA-122. Indeed, introduction
of Amp
miRNA-122 into hepatic cell lines did not lead to any
appreciable increase in the levels of mature miRNA-122.
However, introduction into HEK 293T cells again led to a
>1000-fold increase in the measured levels of mature
miRNA-122 (Figure 3c).
Given that Amp
miRNA-143 exhibited transcriptional
ability, we reasoned that we might be able to exploit the
phenomenon and allow the transcription, in tandem, of
other mature miRNAs. With that in mind, we introduced
the precursor sequence of miRNA-125a at the 30-end of
the original Amp
miRNA-143 and transfected the resulting
construct into Huh-7 cells. Cellular introduction of this
chimeric amplicon resulted in the synthesis of mature
miRNA-143 as well as of mature miRNA-125a at nearly
equivalent levels (Figure 3d). Finally, northern blot was
used to verify mature miRNA production in cells
Figure 2. Transcriptional activity of shorter Amp
miRNA-143 fragments. (a) Schema showing relative lengths of six (A–E) shorter versions of
Amp
miRNA-143 that were subsequently introduced into HEK 293T cells for real-time PCR quantiﬁcation of mature miRNA-143 levels. Color
scheme is the same as in Figure 1a. (b) Fragments as short as 102nt were capable of producing mature miRNA but at levels less than the
original 316-nt amplicon. All experiments were performed in duplicate and relative levels of mature miRNA-143 are shown compared to endogenous
levels in cells transfected with an empty vector (Ø). Data are presented as mean values with 95% CI. All experimental conditions (A–E) were
associated with a signiﬁcantly higher level of mature miRNA-143 than Ø (all adjusted P<0.05), and none were signiﬁcantly diﬀerent from one
another after adjustment. (c) Oligonucleotides encoding the 116bp of Amp
miRNA-143-B were commercially synthesized, annealed and introduced into
HEK 293T cells. Oligo
miRNA-143-B retained similar biosynthetic capacity as compared to Amp
miRNA-143-B. Furthermore, the activity of
Amp
miRNA-143-B was not aﬀected by proteinase K digestion of the construct prior to cellular introduction. All experiments were performed in
duplicate and mature miRNA-143 levels are shown as mean values + 95% CI, compared to cells transfected with an empty vector (Ø).
All three miRNA constructs produced statistically signiﬁcant levels of mature product compared to Ø (each adjusted P<0.001); however, none
of the three was signiﬁcantly diﬀerent from one another in terms of biosynthetic potential.
Nucleic Acids Research,2010, Vol.38, No. 9 2779Figure 3. (a) Biosynthetic activity of Amp
miRNA-143 in diﬀerent human cells. Mature miRNA-143 levels were quantiﬁed in amplicon transfected cells
and are shown relative to endogenous levels in cells transfected with an empty vector (Ø) with associated 95% CI. All experiments were performed in
duplicate, independent experiments. In each cell type, Amp
miRNA-143 increased mature miRNA-143 levels in a statistically signiﬁcant manner
(P<0.05). (b) Varied cellular activity of amplicons encoding pri-miRNA fragments of miRNA-145, 363 and 517a. All amplicons (252–339nt)
were generated from human genomic DNA and transfected into HEK 293T cells in duplicate, independent experiments. Levels of mature
miRNA were quantiﬁed by real-time PCR and are expressed relative to background levels in cells transfected with an empty vector (Ø) and
95% CI. Each Amp species led to a statistically signiﬁcant increase in the levels of the respective miRNA compared to Ø (P<0.0001). (c) The
biosynthetic potential of a given amplicon was quantiﬁable in cells with relatively low endogenous levels of the miRNA studied. For example,
(continued)
2780 Nucleic Acids Research, 2010,Vol.38, No. 9transfected with other amplicons including those encoding
miRNA-363 and 181a-2 (Supplementary Figure S2).
Functionality of Amp
miRNA-XX
While quantitative assays revealed the biosynthetic
activity of Amp
miRNA-XX, we next sought to assess func-
tional capacity. We created miRNA sensors in which the
antisense sequence of a particular mature miRNA was
placed in the 30-UTR of the gene encoding Renilla
luciferase. In the presence of mature miRNA, levels of
Renilla activity decrease through the classical RNAi
pathway. Co-transfection of Amp
miRNA-143 with its
sensor led to a statistically signiﬁcant reduction in
Renilla activity, albeit at levels below those attained with
CMV-driven miRNA-143 expression vector (Figure 4a).
Similar experiments employing the shorter variants
Amp
miRNA-143-A/B/C/D/E/F revealed their functional
Figure 3. Continued
Amp
miRNA-125a signiﬁcantly (P<0.0001) increased levels of mature product in Huh-7 cells (miRNA-125a
low) but not in HEK 293T cells
(miRNA-125a
high). Conversely, Amp
miRNA-122 produced signiﬁcantly (P=0.0008) increased levels of mature product only in HEK 293T cells
(miRNA-122
low) but not in Huh-7 cells (miRNA-122
high). (d) A hybrid amplicon consisting of miRNA-143 and miRNA-125a
(Amp
miRNA-125a+143) was capable of producing both miRNAs at levels comparable to individual expression units after introduction into Huh-7
cells. Relative levels of mature miRNA were quantiﬁed by real-time PCR in duplicate experiments and are shown as mean values and 95% CI. All
Amp
miRNA-XX constructs including the hybrid molecule were associated with a statistically signiﬁcant increase (adj P<0.0001) in the respective
mature miRNA levels compared to cells treated with an empty vector (Ø).
Figure 4. Functional activity of Amp
miRNA-XX. Luciferase-based miRNA sensor assays were used to compare the functional activity of various
miRNA expression units. We created reporter constructs, in which the exact target sequence of a given miRNA was introduced into the 30UTR of
the gene encoding Renilla luciferase and quantiﬁed the relative reduction in luciferase levels compared to control experiments involving the same
sensor but an empty vector (Ø). An internal ﬁreﬂy luciferase gene served to normalize data. All sensor assays were performed as three independent
experiments and data are shown as mean reduction +/– SD compared to control conditions. (a) Functional activity of Amp
miRNA-143,
Amp
CMV-miRNA-143 and Pla
CMV-miRNA-143. Co-transfection of the miRNA-143 sensor and Amp
miRNA-143 led to 57% decrease in luciferase activity,
a statistically signiﬁcant level (P=0.02) approaching that achieved in transfections using a CMV-driven miRNA-143 expression plasmid (81%
reduction) or amplicon (70% reduction) in HEK 293T cells. (b) Functional activity of shorter amplicons Amp
miRNA-143-A/B/C/D/E/F. All constructs
retained functionality as assessed by sensor assays. Shown are statistically signiﬁcant (adjusted P<0.05) reductions in normalized relative light units
(RLU) in cells transfected with the amplicons (A–F) in comparison to cells transfected with an empty vector (Ø). (c) Sensor assays were performed
for an additional nine Amp
miRNA-XX. In each case, sensor activity was decreased in a statistically signiﬁcant manner (adjusted P<0.05) compared to
experiments involving an empty vector (Ø). (d). The ERK5 protein is a target of miRNA-143. Introduction of Amp
miRNA-143 into HEK 293T cells
was associated with a reduction in ERK5 protein levels as determined by western blot. RNAP II-driven plasmid and an empty vector (Ø) served as
positive and negative controls, respectively.
Nucleic Acids Research,2010, Vol.38, No. 9 2781activity as well (Figure 4b). Finally, we used the sensor
assay to examine the activity of nine additional
Amp
miRNA-XX, all of which were expressed at relatively
low levels in HEK 293T cells. In each case, transfection
of Amp
miRNA-XX with its sensor led to a statistically signif-
icant reduction in Renilla activity (Figure 4c). Next, we
asked whether cellular protein levels could be
downregulated by exogenously introduced Amp
miRNA-XX.
Previous work has identiﬁed ERK5 as a target of
miRNA-143 (13). Treatment of HEK 293T cells with
Amp
miRNA-143 led to the relative reduction of ERK5
protein levels as seen in Figure 4d.
Of the 12 miRNA with functional Amp constructs,
we noted that four have had previously detailed
characterization of their promoter regions
(miRNA-26a1,107,122,517a) (14, 15). Signiﬁcantly, in
each case, the corresponding Amp
miRNA-XX species
did not include these promoter motifs yet still led to
mature miRNA production/function upon cellular
introduction.
On the atypical transcriptional nature of Amp
miRNA-143
To date, RNAP II/III promoters have been implicated in
the transcriptional control of miRNA genes, with the
majority of the studied genes being under the control of
RNAP II (4,11,14–16). In an attempt to gain a better
understanding of the transcriptional machinery involved
in the processing of Amp
miRNA-143, we ﬁrst sought to
identify which of the currently known transcriptional
programs mediated endogenous miRNA-143 production
in human cells.
We used chromatin precipitation (ChiP) to look for the
physical presence of RNAP II on the 2.5-kb genomic
region immediately upstream of miRNA-143*. These
experiments utilized HCT116 cells that produce high
levels of mature miRNA-143. PCR primers amplifying
 100–200-nt fragments of the putative promoter region
were immunoprecipitated with IgG against RNAP II
(anti-pol II:8WG16) and revealed RNAP II localization
at  1kb upstream relative to the pre-miRNA-143, i.e. in
an area well outside of the sequence captured by
Amp
miRNA-143 (Figure 5a).
Next, we made use of the limited number of drugs that
are available for diﬀerentiating between the RNAP II and
III mammalian transcriptional programs. The mushroom
toxin a-amanitin is known to adversely aﬀect RNAP II/III
activity in a dose-dependent manner with RNAP II
activity being inhibited at far lower concentrations of
drug. We thus treated HEK 293T cells with a-amanitin
and transfected, in turn, with either the RNAP II/
III-driven miRNA-expressing plasmids or Amp
miRNA-143.
In the case of the plasmids, quantiﬁcation of mature
miRNA-143 levels 8h post-transfection revealed diﬀeren-
tial sensitivity to a-amanitin, with RNAP II activity being
inhibited by >90% and RNAP III activity being inhibited
by 40%. However, and importantly, when we transfected
with Amp
miRNA-143, a-amanitin had no eﬀect on the
amplicon’s biosynthetic activity and the production of
mature miRNA-143 (Figure 5b). We next assessed the
eﬀect of a-amanitin on endogenous miRNA-143
expression. Treatment of HCT116 cells with drug led to
a >90% reduction in pri-miRNA-143 levels compared to
control cells that had been treated with vehicle alone, as
expected from our ChiP experiments that localized RNAP
II to the miRNA-143 gene locus. These data in sum raised
the intriguing possibility that RNAP II was not associated
with the transcription of Amp
miRNA-143. To formally
investigate this possibility, we created biotinylated
versions of Amp
miRNA-143 with and without RNAP II/
III promoter sequences and incubated them in HEK
293T cell lysate. Streptavidin coated bead based retrieval
of the molecules allowed us to localize RNAP II to
Amp
RNAP II-miRNA-143 but not to Amp
RNAP III-miRNA-143
or Amp
miRNA-143 (Figure 5c).
Next, we used actinomycin, a general and more potent
inhibitor of RNA transcription that acts by intercalating
between successive GC base pairs and preventing RNAP
mediated elongation of the nascent transcript (17). In this
case, both RNAP II- and RNAP III-driven plasmids were
exquisitely sensitive to actinomycin with >97% reduction
in their respective biosynthetic function. However,
Amp
miRNA-143 was less sensitive exhibiting only 50%
reduction in function (Figure 5d).
The extremely compact nature of Amp
miRNA-143 and its
products led us to hypothesize that components of RNAP
III machinery may be involved in its transcription (18).
Furthermore, RNAP III has been recently implicated
in the cytosolic transcription of a poly(dA–dT) tem-
plate into 50-ppp RNA (19). Thus, we treated cells
with short interfering RNA (siRNA) targeting the
largest subunit of RNAP III (POLR3A) and mea-
sured the eﬀect on the output of our RNAP III-driven
plasmid and Amp
miRNA-143, respectively (20). As seen
in Figure 5e, siRNA-mediated silencing of
POLR3A inhibited the RNAP III-driven plasmid but
had no eﬀect on Amp
miRNA-143 in two independent
experiments.
Further support for the lack of involvement of RNAP
III in Amp
miRNA-XX transcription derived from more
detailed experiments involving miRNA-517a. As men-
tioned, Amp
miRNA-517a was associated with mature
miRNA production after introduction into HEK 293T
cells. The genetic organization of miRNA-517a is
somewhat unique in that it is a substrate for RNAP III
with a concise organization including the traditional A
and B boxes required for RNAP III docking (Figure 6a)
(4). Importantly, our initial Amp
miRNA-517a was 262nt in
length and did not contain either of the known A or B
boxes located upstream of its pre-miRNA sequence. We
created a series of progressively longer variants of the
original Amp
miRNA-517a, the longest of which contained
both the A and B boxes. Interestingly, segmental trunca-
tions of Amp
miR-517a, with partial or complete removal of
the A and B box motifs, also led to detectable levels of
functional mature miRNA-517a, albeit at levels far lower
than the two amplicon variants (#3 and #4) that included
both boxes (Figure 6b and c). Not surprisingly, cells
treated with a siRNA targeting POLR3A exhibited a
severely compromised ability to transcribe the
miRNA-517a variants that contained either or both of
the A and B boxes. However, in the presence of the
2782 Nucleic Acids Research, 2010,Vol.38, No. 9Figure 5. Deciphering the transcriptional network of Amp
miRNA-143.( a) We assigned RNAP II promoter occupancy to the miRNA-143 gene in
HCT116 cells by chromatin immunoprecipitation using antibodies speciﬁc to RNAP II. Sheared chromatin from HCT116 cells that had been
cross-linked with formaldehyde was immunoprecipitated with anti-RNAP II antibodies. Cross-links were removed and the DNA was puriﬁed.
The promoter region of miRNA-143 was arbitrarily deconstructed into six segments of  100–200nt each. Speciﬁc PCR primers were designed to
amplify each component and revealed relative enrichment in sector D, corresponding to nucleotide position –978 with respect to the pre-miRNA start
site. All values are relative to nonimmune IgG and normalized to an intergenic control region. Antibodies to GAPDH served as a positive control
and revealed  30-fold enrichment in the respective promoter region. The corresponding location of Amp
miRNA-143 is shown and lies outside the
region of RNAP II enrichment. (b) We used various inhibitors of RNAP to test their eﬀect on the biosynthetic activity of Amp
miRNA-143 as well as
RNAP II/III-driven expression constructs. Cells were treated with a-amanitin (50ug/ml) and actinomycin (2ug/ml) and transfected with the various
constructs prior to harvesting and mature miRNA-143 quantiﬁcation by real-time PCR. Data are shown as fold reduction in mature miRNA
(continued)
Nucleic Acids Research,2010, Vol.38, No. 9 2783siRNA targeting POLR3A, the same cells retained fully
their ability to transcribe the shorter Amp
miRNA-517a that
lacked the A and B boxes (Figure 6d). Thus, although
wild-type miRNA-517a is under the control of RNAP
III through the A and B boxes, an amplicon that does
not include A and B boxes appears to operate upon
transfection in a manner similar to the other amplicons
we described earlier.
Besides RNAP II/III, two other polymerases are oper-
ational in mammalian cells: RNAP I and the more
recently described single polypeptide nuclear RNA
polymerase (spRNAP-IV) (20). RNAi-based depletion
of RNAP I or spRNAP-IV had no eﬀect upon the
biosynthetic activity of Amp
miRNA-XX (Supplementary
Figure S3).
Eﬀect of Amp
miRNA-XX on endogenous miRNA expression
Numerous studies have demonstrated that ectopic expres-
sion of small RNA molecules may perturb normal cellular
function through multiple mechanisms. For example,
ectopic expression of shRNA appears to deregulate
endogenous miRNA expression in vitro and perhaps
more importantly, in vivo (21,22). To determine whether
Amp
miRNA-XX species impacted endogenous miRNA
expression, we introduced Amp
miRNA-143 into HEK
293T cells and quantiﬁed the levels of miRNA-let7a,
125a and 125b. These three latter species are relatively
abundantly expressed in HEK 293T cells. As seen in
Figure 7, there was no signiﬁcant diﬀerence in the
endogenous expression of these three miRNA species in
cells that had been transfected with Amp
miRNA-143
Figure 5. Continued
compared to similarly transfected cells in the absence of drug. a-Amanitin signiﬁcantly reduced the biosynthetic activity of RNAP II (P<0.001) and
III (P=0.0384)-driven constructs but had no signiﬁcant eﬀect on the activity of Amp
miRNA-143 (P=1.0). (c) RNAP II was directly localized to
miRNA-143 amplicons harboring the CMV (RNAP II) promoter but not to Amp
miRNA-143 or an amplicon harboring the U6 (RNAP III) promoter.
(d) The general transcriptional inhibitor actinomycin reduced the activity of all constructs in a signiﬁcant manner (P<0.0001) but its eﬀect on Amp
was less pronounced. Data are shown as fold reduction in mature miRNA in drug treated/untreated cells transfected with the indicated constructs.
Experiments were performed in duplicate. (e) Eﬀect of RNAP III silencing on Amp
miRNA-143. HEK 293T cells were treated with siRNA against the
POLR3A subunit of RNAP III or an irrelevant gene and transfected with either empty vector (Ø), Pla
U6-miRNA-143 or Amp
miRNA-143. POLR3A
knockdown ( 50–70%) had a signiﬁcant inhibitory eﬀect (P=0.003) on the transcription of RNAP III-driven expression vectors but no eﬀect
(P=1.0) on Amp
miRNA-143 as assessed by mature miRNA-143 quantiﬁcation. Data are shown as fold reduction in mature miRNA compared to cells
transfected with an irrelevant siRNA. Experiments were performed in duplicate.
Figure 6. (a) Schema showing various sized amplicons (#1–#4) of Amp
miRNA-517a with and without the RNAP III speciﬁc A and B boxes.
(b) Relative amount of mature miRNA-517a produced upon cellular introduction of the various constructs was quantiﬁed by real-time PCR as
compared to cells transfected with an empty vector (Ø). While A and B box inclusive amplicons produced the highest levels of mature miRNA, the
206-bp amplicon without A/B box retained the ability to produce mature miRNA. Experiments were performed in duplicate and constructs #1–#4 all
produced signiﬁcantly higher levels of mature product than Ø (P<0.05). (c) The functionality of Amp
miRNA-517a was assessed by sensor assays. While
the RNAP III (U6)-driven expression vector retained the most potency ( 80%), shorter amplicons with and without A/B boxes also reduced Renilla
relative light units by  30–40%. All constructs signiﬁcantly inhibited sensor activity (P<0.005). (d) Eﬀect of silencing RNAP III on Amp
miRNA-517a
amplicons. Cells were treated with anti-POLR3A or an irrelevant siRNA and transfected with amplicons prior to harvesting and quantifying mature
miRNA-517a levels. RNAP III knockdown had no eﬀect on Amp
miRNA-517a biosynthetic activity (P=0.17) yet signiﬁcantly decreased the synthetic
capacity of both RNAP III-driven expression vector (P=0.0006) and amplicons harboring A/B boxes (P=0.0001).
2784 Nucleic Acids Research, 2010,Vol.38, No. 9compared to cells that had been transfected with an empty
vector or a RNAP II-driven miRNA-143 expression
plasmid.
Engineered miRNA-like molecules do not participate in
atypical transcription
Our experiments suggested that the miRNA species
examined above possessed either sequence and/or struc-
tural determinants that enabled the recruitment of an
unconventional transcriptional machinery. To gain mech-
anistic insight into the perplexing nature of atypical tran-
scription, we ﬁrst compared the nucleotide sequence of the
various miRNA associated with functional amplicons and
could not identify a conserved sequence motif. All
amplicons, however, shared two major attributes upon
transcription: their hairpin-like RNA structure and subse-
quent stereotypic processing by RNAase III enzymes into
shorter fragments of mature and (*) miRNA and possibly
other 21–22-nt fragments, such as the recently
characterized miRNA-oﬀset RNA (23,24). We reasoned
that as long as the hairpin structure and Dicer/Drosha
processing sites were maintained, the primary sequence
of any given Amp
miRNA-XX species could be altered yet
remain functional. Previously, we and others have
demonstrated that the miRNA backbone can be
modiﬁed to include sequences of a given siRNA and
thereby serve as eﬃcient vectors of delivery upon incorpo-
ration into RNAP III-driven expression cassettes (25).
Thus, we introduced sequences encoding a previously
validated siRNA targeting HIV-1 tat into the backbone
of miRNA-143 (Figure 8a). Unexpectedly, when
miRNA-143/tat was PCR-ampliﬁed and introduced as a
promoter-less Amp, we could not detect tat siRNA
expression. However, introduction of an RNAP
III-driven expression cassette harboring miRNA-143/tat
into HEK 293T cells led to tat shRNA detection, as
assessed by northern blot (Figure 8b). Thus, the
sequence replacement did not prevent the molecule’s
entry into and processing by the cellular RNAi machinery
upon placement of the construct under the direction of a
strong promoter. Similar negative results were encoun-
tered when tat siRNA sequences were embedded in
miRNA-30a (data not shown). The only seeming distinc-
tion between functional Amp
miRNA-XX versus
non-functional Amp
miRNA-/tat was the replacement of
mature and (*) miRNA sequences with those encoding
the tat siRNA guide and passenger strand, respectively.
It was entirely unclear to us why engineered miRNA/tat
molecules failed to undergo atypical transcription when
delivered as Amp. We next modiﬁed the miRNA-143
backbone such that mature and (*) sequences were
replaced with those encoding miRNA-145. Introduction
of this hybrid molecule led to the production of mature,
functional miRNA-145 in a statistically signiﬁcant manner
(Figure 8c and d). Thus, alteration of the miRNA
backbone in and of itself does not appear to impact the
biosynthetic potential of Amp as much as the choice of
cargo.
DISCUSSION
In summary, we report our ﬁndings of atypical
self-transcription upon cellular introduction for several
DNA segments, collectively referred to here as
Amp
miRNA-XX, which contain the precursors for known
human miRNA that are devoid of any known exogenous
promoters. The majority of miRNA (8/12) that we studied
were intergenic and thus expected to be transcribed with
their host genes (15). A recent promoter analysis localized
transcription start sites of miRNA-26a, 30a, 107 and 122
at several thousand nucleotides from the beginning of
their respective pre-sequences. Our experiments, which
included these and other miRNA, however, indicated
that a cryptic transcriptional element was present in the
sequence of the pri/pre-sequences of the intronic and
intergenic miRNA genes examined. Our analysis also
revealed altered sensitivity of Amp
miRNA-XX to
pharmacologic and/or genetic knockdown of RNAP I/
II/III, thus raising the possibility of an atypical
transcriptional program involving pri-miRNA gene frag-
ments. The absence of any apparent shared sequence
features among the diﬀerent amplicons that we
employed suggests the formation of a likely novel
scaﬀold that is able to recruit the necessary factors
required for transcription. The precise components of
this scaﬀold await identiﬁcation but replacement of
mature and (*) sequences of a bonaﬁde miRNA with
those encoding siRNA leads to a non-functional
molecule. These results raise the intriguing possibility
that mature and (*) sequences are perhaps themselves
involved in enabling miRNA fragment transcription but
this conjecture clearly needs vigorous investigation.
From the experiments described earlier, we conclude
that at least some of the miRNA precursors that are
currently known in the literature have the ability to
self-transcribe their own sequence fragments, and can do
so in a number of diﬀerent human cell types.
Transcription eﬃciency is lower by comparison to that
of plasmid systems or PCR amplicons employing RNAP
Figure 7. Eﬀect of Amp
miRNA-143 on endogenous miRNA levels. HEK
293T cells were transfected with empty vector (Ø), Pla
CMV-miRNA-143
and Amp
miRNA-143. Real time PCR quantiﬁcation of endogenous
miRNA (let 7a, 125a,125b) in transfected cells revealed no statistically
signiﬁcant diﬀerence in respective mature miRNA levels between Ø,
Pla
CMV-miRNA-143 and Amp
miRNA-143 transfected cells.
Nucleic Acids Research,2010, Vol.38, No. 9 2785II/III promoters; consequently, the phenomenon can be
observed readily only against a backdrop of minimal
expression for the studied miRNA.
To date, means of expressing miRNA in cells include
their delivery in plasmid or viral vectors as well as direct
delivery as synthetic molecules. Our ﬁndings suggest that
it might be possible to engineer expression of at least a
handful of miRNAs simply by introducing the corre-
sponding miRNA precursor fragments in the form of syn-
thetic or PCR-generated DNA automatons devoid of
traditional promoters into targeted cells in vitro or entire
organisms in vivo.
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